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Stratum corneumThe present investigation focused on the development of Diltiazem HCl (DTH) matrix ﬁlm and
its characterization by in-vitro, ex-vivo and in-vivo methods. Films were prepared by solvent
casting method by taking different ratios of hydroxypropyl methylcellulose K4M (HPMC
K4M) and Eudragit RS100. Various parameters of the ﬁlms were analyzed such as mechanical
property using tensile tester, interaction study by Fourier transform infrared spectroscopy
(FTIR) and Thermogravimetric analysis (TGA), in-vitro drug release through cellulose acetate
membrane, ex-vivo permeation study using abdominal skin of rat employing Franz diffusion
cell, and in-vivo antihypertensive activity using rabbit model. The FTIR studies conﬁrmed the
absence of interaction between DTH and selected polymers. Thermal analysis showed the shift-
ing of endothermic peak of DTH in ﬁlm, indicating the dispersion of DTH in molecular form
throughout the ﬁlm. Incorporation of 1,8-cineole showed highest ﬂux (89.7 lg/cm2/h) of DTH
compared to other penetration enhancers such as capsaicin, dimethyl sulfoxide (DMSO), and
N-methyl pyrrolidone (NMP). Photomicrographs of histology study on optimized formulation
(DF9) illustrated disruption of stratum corneum (SC) supporting the ex-vivo results. The in-vivo
antihypertensive activity results demonstrated that formulation DF9 was effective in reducing
arterial blood pressure in normotensive rabbits. SEM analysis of ﬁlms kept for stability study
(40 ± 2 C/75%± 5%RH for 3 months) revealed the formation of drug crystals which may
be due to higher temperature. The ﬁndings of the study provide a better alternative dosage form
of DTH for the effective treatment of hypertension with enhanced patient compliance.
 2015 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
L-type of calcium channel mediated Ca+ inﬂux plays a major
role in the regulation of blood pressure and manifestation of
hypertension [1]. Accordingly, speciﬁc L-type of calcium chan-
nel blockers is used to prevent the entry of Ca+ into the cell
which results in vascular smooth muscle relaxation and subse-
quently vasodilatation. Out of three classes (phenylalkylamines,
540 R. Parhi and P. Sureshdihydropyridines and benzothiazepines) of Ca+ channel block-
ers available for clinical use, DTH, (2S,3S)-5-[2-(dimethyl-
amino) ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,
5-benzothiazepin-3-yl acetate hydrochloride belongs to ben-
zothiazepines class [2]. Apart from its antihypertension applica-
tion, DTH is also a drug of choice in the management of classical
and vasospastic angina pectoris, supraventricular tachyarrhyth-
mias and anal ﬁssure [3]. Oral administration of DTH subjected
to extensive and complex biotransformation (N-demethylation,
O-demethylation and deacetylation) which limits the biological
half-life to 3–5 h and bioavailability up to 40% [4]. The drug
dosage recommended for DTH is 30 mg or above, usually three
to four times a day [5]. The above conditions provide a strong
rationale for the development of a transdermal formulation
for DTH.
Compared to other routes, transdermal route is proved to be
advantageous due to the following reasons: (i) better patient
compliance as the administration is convenient and non-
invasive in nature, (ii) reduction in dosing, (iii) avoidance of
ﬁrst pass metabolism and (iv) prevention of gastrointestinal
irritation due to the contact of certain active ingredients to gas-
tric mucosa [6]. Among transdermal systems, self-adhesive ﬁlms
are considered as an innovative drug delivery system to achieve
systemic effect through skin application [7]. Out of various
transdermal drug delivery systems such as matrix, reservoir,
microreservoir, membrane matrix hybrid and adhesive, matrix
diffusion type is widely accepted because of its ease of manufac-
turing. Many researchers have successfully developed ﬁlms of
DTH using combination of different polymers including ethyl
cellulose–PVP, Eudragit–PVP–PEG 4000, HPMC–EC [8], taro
corn mucilage–HPMC [9] and PVA–xanthan gum [5].
Due to impervious SC layer of the skin very few drugs have
the ability to penetrate the skin in sufﬁcient quantity in order
to produce the required therapeutic effect. Various physical
techniques and chemical penetration enhancers have been tried
to breach this barrier nature of skin. Penetration enhancers are
more popular than physical methods due to lack of pain at the
application site [10]. Penetration enhancers increase the drug
penetration across the skin by interacting with skin’s bilipid
layer component, thereby causing increased ﬂuidity in the
intercellular lipid lamellae, swelling in the SC and/or leaching
out some of the structural components. In addition, penetra-
tion enhancers may react with protein structure of the SC
and thereby pronouncing the penetration of active ingredients.
Among all, terpenes are considered as Generally Recognized
As Safe (GRAS) category of penetration enhancers which
could be used between 1% and 5% without any side effects
to enhance either hydrophilic or lipophilic drugs penetration
across the skin [11]. So, we selected 1,8-cineole as terpene along
with NMP, capsaicin and DMSO as penetration enhancers to
improve the ﬂux of DTH through abdominal skin of rat.
Our objective was to develop and evaluate matrix diffusion
controlled system of DTH using the combination of hydropho-
bic (Eudragit RS100) and hydrophilic (HPMC K4M) poly-
mers. Different proportion of polymers was taken into
consideration to select the best combination. In addition, the
effect of plasticizers such as glycerin, DBT and propylene gly-
col (PG) on the ﬁlm characteristics was also evaluated. The
ﬁlms were tested for physicochemical properties, mechanical
characteristics, FTIR studies, thermal analysis, in-vitro release
study, ex-vivo permeation using abdominal skin of rat, in-vivo
study utilizing rabbit model and stability studies.Material and methods
Materials
DTH (P99%) and HPMC K4M were generous gifts of Ran-
baxy Laboratories Pvt. Ltd., Gurgaon, Haryana, India.
Eudragit RS100 was gifted by Evonik Degussa India Pvt.
Ltd., Mumbai, India. Capsaicin and cellulose acetate mem-
brane (molecular weight cutoff between 12,000 and
14,000 Da) were purchased from HiMedia Laboratories Pvt.
Ltd., Mumbai, India. Methanol and 1,8-cineole were obtained
from Merck Specialties Pvt. Ltd., Mumbai, India. NMP and
DMSO were obtained from CDH, New Delhi. DBT purchased
from Loba Chemie, Mumbai. All other chemicals used during
experiment were of analytical grade.
Preparation of films
Diltiazem HCl (30% w/w of dry weight of total polymer)
loaded transdermal ﬁlms containing different ratios of HPMC
K4M and Eudragit RS100 were prepared by solvent casting
method. The requisite ratios of polymers were weighed and
were allowed to swell for 6 h in methanol–dichloromethane
(1:1) solvent mixture. Different plasticizers such as glycerol,
DBT and PG were incorporated at 20% w/w of polymer dry
weight. Calculated amount of DTH was mixed with homoge-
nous polymer solution and poured into a petri dish containing
mercury [12,13]. A funnel was placed over the petri dish in
inverted position to control the rate of evaporation. The cast-
ing solvent mixture was allowed to evaporate overnight at
room temperature. The dried ﬁlms were cut into required size
(1.6  1.6 cm2) and wrapped in aluminum foil. Then, these
ﬁlms were kept in desiccator containing saturated solution of
CaCl2 as desiccant (29% of relative humidity) at room temper-
ature (32 C) until use. DMSO, 1,8-cineole, capsaicin and
NMP were incorporated at 5% w/w of dry weight of polymer
in optimized ﬁlm.
Evaluation of the physicochemical properties of the films
Thickness and weight variation
Thickness of the prepared ﬁlms was measured at six different
places using digital vernier caliper (Mitutoyo, Japan) and the
mean was calculated [14]. Six ﬁlms (2.56 cm2) from each batch
were randomly selected for weight variation. Films were
weighed individually and then the average weight was mea-
sured. The difference between individual and average weight
indicated the weight variation.
Folding endurance
A strip of ﬁlm of speciﬁc surface area (3 cm  2 cm) was cut
and folded repeatedly at one place till it broke. The number
of times the ﬁlm was folded before breaking at the same place
represented folding endurance [12].
Drug content analysis
For drug content analysis, ﬁlms of known area were taken in
10 ml of volumetric ﬂask and casting solvent mixture was
added to it. The ﬂasks were shaken in a water bath at 37 C
for 24 h. Then, the solution was ﬁltered through Whatman
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measurement using UV–Vis spectrophotometer (UV-1800,
SHIMADZU, Japan) at 236 nm.
Moisture content
The ﬁlms of DTH were weighed individually and kept in a des-
iccator containing saturated solution of CaCl2 (29% of relative
humidity) at room temperature (32 C) for 24 h. Subsequently,
the ﬁlms were weighed repeatedly until a constant weight was
achieved. The percentage of moisture uptake was calculated
based on the difference between ﬁnal and initial weight divided
by initial weight [13].
Moisture uptake
The weighed ﬁlms kept in a desiccator for 24 hat room temper-
ature (32 C) were taken out and exposed to 75% relative
humidity (saturated solution of NaCl) until a constant weight
was obtained. The percentage of moisture uptake was calcu-
lated as the difference between ﬁnal and initial weight divided
by initial weight [8,13].
Water vapor permeability
For water vapor permeability (WVP) measurement, glass test
tubes of 25 mL capacity were taken and ﬁlled with 20 mL of dis-
tilled water. The weight of each ﬁlled test tube was measured
one hour prior to closing the openings by ﬁlms. The area avail-
able for vapor permeation was 2.544 cm2 and all the containers
were maintained at constant room temperature (32 C) for 24 h.
The ﬁnal weight was calculated after one hour of test comple-
tion and the WVP was calculated using the following equation:
WVP ¼W=A ðg=m2  24 hÞ
whereW is the mean loss in weight (g) of the containers and A
(m2) is the area of the exposed surface [15].
Mechanical properties
The mechanical properties such as ultimate tensile strength
(UTS), Young’s modulus and elongation at break (EB) were
measured using universal tensile testing machine (INSTRON
3366, USA Inc). The clamps of tester were covered with silicon
gum to prevent slippage of the ﬁlms during the test. Then, the
ﬁlms were driven downward using 10 N load sensor with a
ﬁxed speed of 10 mm/min until breaking of the ﬁlm. The
UTS, EB (%) [15] and Young’s modulus were calculated as
per the following equations:
UTS ¼ Breaking force
Cross-section area of film
EB ð%Þ
¼Length at breaking point of filmOriginal length of film
Original length of film
100
Young’s modulus ¼ Tensile Stress
Tensile StrainFourier transform infrared spectroscopy (FTIR) study
FTIR spectra of pure DTH and individual polymers
(HPMCK4M and Eudragit RS100) were recorded along withtheir physical mixtures in a FTIR spectrophotometer (Alpha-
FT-IR, Bruker Optics, Germany) using KBr pellets technique
over the range of 4000–500 cm1.
Thermal analysis
Thermal analysis of DTH, HPMC K4M and Eudragit RS100
and the optimized ﬁlm (DF9) was performed using differential
thermal analyzer (DTG-60, simultaneous TGA/DTA analyzer,
Shimadzu, Japan). Samples were heated from 0 C to 600 C at
a rate of 10 C/min in a nitrogen purge of 50 ml/min.
In-vitro release studies
The in-vitro release of DTH from the prepared ﬁlm was per-
formed using vertical type of Franz diffusion cell (Murthy
glasswares, Hyderabad, India) with an exposed surface area
of 3.8 cm2 and receptor compartment capacity of 22 mL. The
jacketed diffusion cell with inlet and exit port for the circula-
tion of water was used in order to maintain medium tempera-
ture at 32 ± 0.5 C. A ﬁlm specimen of surface area 2.56 cm2,
equivalent to 15 mg of the drug was placed on 0.22-lm cellu-
lose acetate membrane. The membrane was equilibrated by
soaking in phosphate buffer pH 7.4 for 24 h prior to the exper-
iment. The above medium was used to ensure the sink condi-
tion and stability of the drug. The membrane having ﬁlm on
it was immediately placed between the chambers (donor and
receptor) and subsequently, secured ﬁrmly by a stainless steel
clip. The receptor compartment was stirred at 200 rpm with
a Teﬂon coated magnetic bead. Aliquots of 0.5 ml were with-
drawn from the receptor medium at speciﬁed time intervals
(0.5, 1, 2, 3, 4, 5, 6, and 8 h) and replaced with equal volumes
of fresh buffer maintained at same temperature. The samples
were analyzed using a UV-Spectrophotometer at 236 nm after
suitable dilution and the concentrations of DTH were calcu-
lated using calibration curve.
Ex-vivo permeation studies
Skin preparation
The male Wister rats (200–250 g) were collected once the
experiment on them was completed. The rat abdomens were
shaved using electric clipper and then with hand razor from
tail to head direction. The skin was removed surgically and
adhering subcutaneous fat was carefully cleaned with forceps
and cotton swab. The skin pieces were washed thrice with
phosphate buffer pH 7.4 and wrapped in aluminum foil. Then,
it was stored in deep freezer and was used on the following day
[16].
Ex-vivo permeation study
The ex-vivo permeation study of DTH through abdominal skin
of rat was performed using the same diffusion cell with all the
conditions (receptor compartment was ﬁlled with 22 mL phos-
phate buffer of pH 7.4 maintained at 32 ± 0.5 C with contin-
uous stirring) as mentioned above. A thawed piece of skin was
hydrated in receptor medium for 1 h followed by mounting it
on receptor compartment such that the SC end is faced toward
donor compartment. A desired size (1.6  1.6 cm2) of opti-
mized ﬁlm specimen with and without penetration enhancers
was placed over the hydrated skin and then it was securely
clamped between donor and receptor compartment. At speciﬁed
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receptor medium and the concentration of DTH was analyzed
by HPLC assay as mentioned below.
The HPLC system consisted of an Agilent HP 1100 series
equipped with autosampler and DAD detector (G1315B). A
reverse-phase C18 column (150  4.6 mm, Luna C18 column,
5 lm) with a guard column was used as the stationary phase
at 25 C. The mobile phase used was a mixture of acetonitrile
and phosphate buffer of pH 3 in 6:4 ratio. The injection vol-
ume was 30 lL and the ﬂow rate was set at 1.2 mL/min.
DTH was detected at 236 nm and the retention time was
10 min. The proposed method was validated for linearity and
precision and accuracy. The linearity was evaluated by deter-
mining DTH at ﬁve concentration levels: 10.0, 20.0, 30.0,
40.0, and 50.0 lg/mL. The precision and accuracy of the above
method was established by analyzing pure samples of DTH.
Three concentration levels (10.0, 20.0, and 30.0 lg/mL) were
analyzed within one day as well as for ﬁve consecutive days.
Each concentration level was analyzed three times and stan-
dard deviations (SD) of each concentration were analyzed.
In-vivo study
The antihypertensive activity was performed on normotensive
rabbits (New Zealand white rabbit) as per the standard
operating procedure of Deshpande Lab, Bhopal, India. All
animal experiments were performed according to the ‘‘CPCSEA
Guidelines for the Care and Use of Laboratory Animals”, India,
with approval no. DL/RP/2014/a. Brieﬂy, nine rabbits in three
groups having equal number in each group were considered in
this study and the grouping was made as follows:
Group I was applied with ﬁlm without drug (ve control
group),
Group II was received per-oral drug solution (+ve control
group), and
Group III was applied with ﬁlm containing DTH.
Rabbits were housed in individual cages with sufﬁcient
access to pellet diet and water. The temperature of 25 C
and relative humidity of 55 ± 10% were maintained in the ani-
mal room. Invasive method was employed to determine anti-
hypertensive effect of optimized formulation (DF9) and oral
drug solution in rabbits and the result was compared with
ve control group. Each rabbit of the second group has
received pure drug solution (5 mg/kg) orally. In another two
groups, thigh regions were shaved using a razor to prepare
3.5  3.5 cm area for the ﬁlm sample application. Film without
DTH and optimized ﬁlm piece equivalent to 30 mg of DTH
was applied on shaven skin area of rabbits of ve control
and tested groups, respectively. In this study, higher dose of
DTH was applied transdermally compared to oral dose. The
objective was to maintain maximum drug concentration or sat-
urated state of drug when applied transdermally in the donor
compartment to obtain maximum thermodynamic activity
[17]. After 1 h, ear artery was palpated and local anesthesia lig-
nocaine (2%) was applied subcutaneously around the artery.
Then, an arterial catheter (A-line) containing heparinized sal-
ine was inserted to the ear artery. The arterial line was con-
nected to manometer (Ludwig) to record invasive arterial
blood pressure [18]. The measurement was carried out at pre-
determined time intervals of 1, 2, 4, 6, 8, 12 and 24 h andexpressed in percentage decrease in arterial blood pressure in
comparison with ve control group.
Histological studies
Two skin samples (control and treated) were used in histology
study. The control skin sample was collected without any
treatment whereas the treated one was collected once the ex-
vivo permeation on the optimized ﬁlm (DF9) was completed.
Each specimen was stored in 10% formalin solution in HPLC
water prior to the experiment. The skin samples were sectioned
carefully without damage, treated with absolute isopropyl
alcohol for dehydration, ﬁxed in parafﬁn wax, and stained
with xylol. The resulted specimen was then observed under a
light microscope (Microtome-1200 Weswox, Western electrical
scientiﬁc work).
Scanning electron microscope (SEM) and stability studies
The morphological character of the optimized fresh and aged
ﬁlm was studied by scanning electron microscopic method.
The aged ﬁlm, used in this study, was generated by keeping
a fresh ﬁlm in accelerated stability condition (40 ± 2 
C/75%± 5%RH in a stability chamber, JRIC 11, Osworld,
Mumbai, for 3 months) [19]. The sample ﬁlms were mounted
on a clear-glass stub, air-dried and coated with polaron
E5100 sputter coater. Then, it was visualized under a SEM
(Leo-435 VP; Leo, Cambridge, UK).
Statistical analysis
One way analysis of variance (One-way ANOVA) with Bonfer-
roni multiple comparison test was used to measure statistical
signiﬁcant differences between various data obtained from dif-
ferent evaluation tests at 95% conﬁdential level (P< 0.05). It
was performed employing demo version of GRAPHPAD
INSTAT software (Graph-Pad Software Inc., San Diego, CA).
Results and discussion
All the ﬁlms were prepared by solvent casting method using
methylene chloride and methanol in 1:1 ratio as solvent sys-
tem. Films from DF1 to DF4 were developed with plasticizer
glycerol, whereas DF5 and DF6 were prepared using DBT
and PG, respectively. The composition of all ﬁlms is men-
tioned in Table 1.
The calibration graph was constructed between the stan-
dard concentrations of DTH and area (lV sec) measured at
236 nm. The correlation coefﬁcient (R2) value was found to
be 0.998, which showed a linear response in the concentration
range of 10–50 lg/ml. The accuracy and precision of the devel-
oped method was performed by carrying out ﬁve independent
analyses at each concentration level and the result is shown in
Table 2.
Evaluation of the physicochemical properties of the films
Thickness and weight variation
The thickness of the prepared ﬁlms was varied between 270
± 30 lm and 240 ± 0 lm as shown in Table 3. This indicates
Table 1 Composition of all transdermal ﬁlms of DTH.
Film code HPMC (mg) ERS (mg) Glycerol (mg) DBT (mg) PG (mg) DMSO (mg) 1,8-Cineole (mg) Capsaicin (mg) NMP (mg)
DF1 1000 – 200 – – – – – –
DF2 750 250 200 – – – – – –
DF3 500 500 200 – – – – – ––
DF4 250 750 200 – – – – – –
DF5 500 500 – 200 – – – – –
DF6 500 500 – – 200 – –– – –
DF7 500 500 – – 200 50 – – –
DF8 500 500 – – 200 – 50 – –
DF9 500 500 – – 200 – – 50 –
DF10 500 500 – – 200 – – – 50
Table 2 Test of accuracy and precision of the developed
method.
Intra-day assay Inter-day assay
Taken Observed Taken Observed
(lg/mL) (lg/mL) (± SD, n = 5) (lg/mL) (lg/mL) (± SD, n = 5)
10 10.01 ± 0.03 10 10.03 ± 0.03
20 20.05 ± 0.08 20 20.05 ± 0.1
30 30.13 ± 0.06 30 30.13 ± 0.04
Transdermal matrix ﬁlm of diltiazem HCl 543that there was no such signiﬁcant difference (P< 0.05) in
thickness among the ﬁlms. Decrease in thickness of ﬁlms
(DF1–DF4) was observed with the decrease in the HPMC
K4M percentage [20]. The variation of weight ranged from
77.93 ± 3.49 to 81.76 ± 5.01 mg. This represents different
proportions of polymers have not such signiﬁcant impact on
weight variation.
Folding endurance
The main aim of the folding endurance study is to test the abil-
ity of the ﬁlm to endure rupture during the application and use
[9]. The folding endurance values were ranged from 240.25
± 7.4 in case of DF1 to 210.1 ± 5.78 in case of DF5 (Table 3).
It was observed that with decrease in HPMC K4M proportion
in the ﬁlm the folding endurance value decreases. When ﬁlm
formulations containing penetration enhancers (DF7–DF10)Table 3 Results of physicochemical parameters.
Film code Thickness (lm) Weight variation (m
(±SD, n= 6) (±SD, n= 6)
DF1 270 ± 30 79.37 ± 4.05
DF2 260 ± 10 78.91 ± 2.15
DF3 250 ± 20 80.84 ± 3.49
DF4 240 ± 0 81.76 ± 5.01
DF5 240 ± 10 77.93 ± 3.49
DF6 250 ± 0 78.39 ± 2.08
DF7 240 ± 20 78.34 ± 1.92
DF8 240 ± 30 77.97 ± 2.19
DF9 250 ± 10 80.54 ± 3.21
DF10 240 ± 0 79.39 ± 3.67were compared, formulation DF8 demonstrated highest value
of folding endurance (245.26 ± 5.79). The higher values
demonstrated that ﬁlms would maintain the integrity and
shape with the natural folding of the skin when applied on it.
Drug content determination
The drug content data showed good uniformity with low stan-
dard deviation. This is an indication that the ﬁlms of DTH
with HPMC K4M and Eudragit RS100 can be prepared with
higher degree of reproducibility.
Moisture content and moisture absorption
The moisture absorption is a tool to indicate how the ﬁlm
would behave during the initial stage of drug release [13].
The result of moisture content and moisture absorption study
is shown in Fig. 1(a). The moisture content and moisture
absorption values varied from 11.34% to 8.2% and from
22.62% to 7.65%, respectively. We did not observe any regular
pattern of increase or decrease of moisture content among the
formulations. However, there was a decreasing order of mois-
ture absorption from polymer ratio (HPMC K4M:Eudragit
RS100) of 100:0 (DF1) to 25:75 (DF4). This is obvious that
with increase in hydrophilic polymer proportion there was
an increase in the moisture absorption capacity of the ﬁlms.
The change in moisture content and moisture absorption
among the ﬁlm formulations containing different types of
penetration enhancers (DF7–DF10) was found to be
non-signiﬁcant (P< 0.05) suggesting that the presence of
penetration enhancers has negligible impact on above properties.g) Folding endurance Drug content (mg)
(±SD, n= 6) (±SD, n= 6)
240.25 ± 7.4 14.97 ± 0.08
234.0 ± 3.0 14.96 ± 0.05
228.36 ± 4.5 15.01 ± 0.03
213.5 ± 12.56 14.99 ± 0.01
210.1 ± 5.78 14.95 ± 0.04
219.8 ± 3.29 14.94 ± 0.02
239.45 ± 9.87 14.97 ± 0.02
245.26 ± 5.79 15.02 ± 0.06
215.89 ± 3.54 14.98 ± 0.01
221.54 ± 4.58 15.00 ± 0.03
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Fig. 1 (a) Percentage of moisture content and moisture absorp-
tion by different ﬁlms containing DTH, and (b) percentage of
water vapor permeation through the ﬁlms containing DTH.
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The water vapor permeability (WVP) values of the prepared
ﬁlm are shown in Fig. 1(b). All the WVP values were found
to be ranging between 388.85 ± 30.85 g/m2/day in case of
DF4 and 766.66 ± 34.53 g/m2/day in case of DF1. It was
observed that increasing the Eudragit RS100 proportion in
the ﬁlm decreases the WVP values which could be attributed
to the water insoluble nature of the Eudragit polymer. The
average transepidermal water loss by diffusion through the
skin is 300–400 ml/day which corresponds to 157.894–
210.526 g/m2/day (the normal body surface area was
considered as 1.9 m2) [21]. According to BP 1993, the limitTable 4 Mechanical properties of transdermal ﬁlms containing DT
Film code UTS (MPa) Elo
DF1 42.877 ± 3.963 116
DF2 24.165 ± 3.678 58
DF3 10.285 ± 2.336 50
DF4 05.328 ± 1.223 32
DF5 12.173 ± 2.591 40
DF6 09.369 ± 1.745 47
DF7 09.975 ± 2.423 48
DF8 17.179 ± 2.513 37
DF9 08.054 ± 1.237 45
DF10 09.127 ± 2.452 43
n= 3.above which a substance is considered as permeable is
500 g/m2/day. All the WVP values were above this limit except
DF4 (388.85 ± 30.85) with the highest value of 766.66
± 34.53 in case of DF1. This indicated that the prepared ﬁlms
were not occlusive in nature and thereby not disturbing natural
process of water loss from body surface. The decreasing order
of WVP values was observed from DF1 to DF4. This result
was attributed to decrease in hydrophilic polymer proportion
in the ﬁlm. It was also observed that the addition of different
penetration enhancers does not inﬂuence the WVP signiﬁ-
cantly (P< 0.05).
Mechanical properties
The mechanical properties such as UTS, EB% and Young’s
modulus of all the ﬁlms were measured and the data are shown
in Table 4. A hard and tough polymeric ﬁlm, generated from
high values of both UTS and EB%, is always desired as it
has qualities suited best as a drug delivery system for the skin
application. This implies that higher UTS values prevent abra-
sion of the ﬁlm caused for example by contact with clothing
whereas higher EB% values allow the ﬁlm to follow the move-
ment of skin without breaking. In case of ﬁlms (DF1–DF4),
containing glycerin as plasticizers, a decreasing trend in all
the above parameters from DF1 to DF4 was observed with
highest value for ﬁlm DF1. Decreasing trend of UTS, and
EB (%) may be due to decrease in HPMC K4M proportion
from 100% in case of DF1 to 25% in case of DF4. Formula-
tion DF5 containing DBT as plasticizers demonstrated highest
value of UTS (12.173 ± 2.591 MPa) and lowest percentage of
EB (40.913 ± 6.134) when the ﬁlms containing different plas-
ticizers such as glycerol, DBT and PG at 20% concentration
level were compared. This result was attributed to the
hydrophobic nature of DBT which increased the strength but
reduced elasticity [22]. Similar type of result was obtained
when formulation containing penetration enhancers (DF7–
DF10) was compared. Formulation DF8 incorporated with
1,8-cineole (hydrophobic) showed highest UTS value of
17.179 ± 2.513 MPa and lowest EB% value (37.451
± 5.246). Young’s modulus is a measure of materials stiffness
or rigidity. Stiff materials are having higher Young’s modulus
value, thus difﬁcult to stretch or deform. The Young’s modu-
lus values were found to be highest (618.457 ± 65.864 MPa) in
case of DF1 indicating more force is needed to deform it com-
pared to other ﬁlm formulations.H.
ngation at break (%) Young’s modulus (MPa)
.528 ± 15.281 618.457 ± 65.864
.481 ± 4.006 415.855 ± 33.351
.833 ± 12.109 260.668 ± 58.063
.482 ± 4.782 145.283 ± 17.192
.913 ± 6.134 209.552 ± 47.569
.782 ± 7.205 245.916 ± 39.729
.458 ± 5.647 243.457 ± 28.574
.451 ± 5.246 197.278 ± 21.782
.316 ± 1.764 247.348 ± 41.358
.192 ± 4.654 245.1233 ± 6.127
Transdermal matrix ﬁlm of diltiazem HCl 545Fourier transform infrared spectroscopy (FTIR) study
FTIR study was performed to investigate the type of interac-
tion between drug and polymers. The spectra of pure DTH,
Eudragit RS100 and HPMCK4M and their physical mixtures
are shown in Fig. 2(a). The principal peaks of pure DTH are
1680.21 cm1 for C‚O (ketone) stretching, 1511.11 cm1 for
C‚C (aromatic ring) stretching, 1255.12 cm1 for CAO
(ether) stretching and 1026.86 cm1 for RAOAR. The other
peaks present with pure DTH spectra were at 3441.91 cm1
NAH stretching, 2966.40 cm1 CAH (aliphatic) stretching,
1743.53 cm1 for C‚O (ester) stretching, 1059.59 cm1 for
CAO (ester) stretching, and 781.78 cm1 for CAH bending.Fig. 2 Interaction studies: (a) FTIR spectra of pure drug, polymer
polymers and optimized ﬁlm (DF9).The FTIR spectra showed that the all the principal peaks
were intact and the absence of any additional peak in all phys-
ical mixture of drug and polymers indicates that there were no
interactions between the above functional groups of drug with
polymers.
Thermal analysis
The thermogram of a drug sample demonstrates a single sharp
endothermic peak and a broad peak indicating melting point
and decomposition temperature, respectively. The DTA-
thermogram of DTH in Fig. 2(b) showed a sharp endothermic
peak at 205.17 C and a broad peak at 275.15 C. Thes and their physical mixture, and (b) thermograms of pure drug,
546 R. Parhi and P. Sureshpolymers Eudragit RS100 and HPMC K4M showed sharp
endothermic peaks at 365.74 C and 339.75 C, respectively,
representing their melting point.
The thermogram of ﬁlm showed a smaller and shifted
endothermic peak from 205.17 C to 198.74 C. Shifting of
peak was not deﬁnitely due to interaction as FTIR spectra of
physical mixtures showed no sign of interaction. This may be
due to the conversion of crystalline form of DTH to amor-
phous form in the ﬁlm [17]. It was expected as DTH was com-
pletely dissolved in organic solvent system chosen thereby
dispersed in the molecular form in hydrophilic polymer
(HPMC K4M). Another shifted peak at 349.65 C represents
the endothermic peak for polymers.
In-vitro release studies
In-vitro drug release proﬁles of transdermal ﬁlm (DF1–DF6)
containing different ratios of HPMC K4M and Eudragit
RS100 are shown in Fig. 3(a). Among the ﬁlms having differ-
ent proportions of polymers (DF1–DF4), DF1 demonstrated
the highest DTH release (66.511 ± 2.79) at the end of 24 h
which was signiﬁcantly different (P< 0.05) from formulations
DF3 and DF4. It was observed that the release of DTH0 
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Fig. 3 The in-vitro and ex-vivo study results: (a) comparison of
in-vitro DTH release from different ﬁlms (DF1–DF10), and
(b) ex-vivo permeation proﬁles of DTH from various ﬁlms
(DF6–DF10) having different permeation enhancers.decreased substantially as the percentage of HPMC K4M
decreased from DF1 (having matrix made from 100% of
HPMC K4M) to DF4 (containing 25% of HPMC K4M). This
may be explained due to the hydrophilic nature of HPMC with
high water absorption property which when in contact with
hydrated membrane exhibits rapid polymer dissolution [8,12].
Furthermore, the fraction of drug present on the surface of
the ﬁlm could also be a contributor to the higher release [23].
The drug release from the ﬁlms (DF3, DF5 & DF6) was
also evaluated to predict the inﬂuence of different plasticizers
(Glycerin, DBT and PG) on in-vitro drug release. The highest
(60.048 ± 1.51%) and lowest (56.292 ± 1.97%) drug release
was found to be in case of DF3 and DF5 containing glycerin
and DBT, respectively. This may be due to the hydrophilic nat-
ure of glycerin, thereby, increasing the drug solubility of DTH
(a hydrophilic drug) and subsequently the drug diffusion. Sim-
ilar trend of DTH release was observed among the ﬁlms con-
taining penetration enhancers (DF7–DF10). The ﬁlm DF8
containing hydrophilic penetration enhancer (1,8-cineole)
showed the highest cumulative percentage of DTH release
(63.448 ± 2.89%). The drug release was found to be in the
decreasing order of DF8 > DF10 > DF7 > DF9. Film for-
mulations containing different plasticizers and penetration
enhancers did not exhibit signiﬁcant difference in drug release
(P< 0.05).
Study of kinetics and mechanism of drug release
To understand the drug release kinetics and mechanism of
drug release, all the in-vitro release data were ﬁtted to various
kinetic models such as zero order, ﬁrst order, and Higuchi
model. The in-vitro release data followed neither zero order
(R2 = 0.897–0.970) nor ﬁrst order kinetics (R2 = 0.621–
0.811), whereas it followed Higuchi model with highest R2
value of 0.994 for DF10 and followed by 0.993 for DF6 as
shown in Table 5. The linearity for Higuchi model indicated
diffusion is the drug release mechanism. In order to know
the type of diffusion all data were ﬁtted to Korsmeyer–Peppas
equation. The diffusion release exponent values (n= 0.507–
0.682) demonstrated anomalous diffusion (non-Fickian model)
i.e., the release mechanism followed the combination of diffu-
sion and swelling. This is attributed to the presence of swelling
polymer HPMC K4M in the matrix [13]. Based on the R2 val-
ues along with the results obtained from physical, mechanical
and release studies, formulation DF6 (R2 = 0.993) was
selected for further study.
Ex-vivo permeation studies
The ex-vivo permeation study was performed using hairless
abdominal skin of rat and the cumulative amount of DTH per-
meated (lg/cm2) was plotted against time as shown in Fig. 3
(b). Among all the formulations, DF9 containing 1,8-cineole
showed highest permeation (2691 lg/cm2) of DTH at 36 h
which was signiﬁcantly different (P< 0.05) from ﬁlm formula-
tions DF6, DF7, and DF8. The same formulation also showed
highest ﬂux (89.7 lg/cm2/h) and permeability coefﬁcient (Kp)
(0.0059) as shown in Table 6. The ﬂux enhancement was found
to be in the following order: DF9 > DF10 > DF8 >
DF7 > DF6. The ﬁlm DF9 showed highest enhancement ratio
(ER) of 6.469.
Table 6 Effect of different ﬁlm formulations on permeation of DTH across abdominal skin of rat.
Film code Flux (lg/cm2/h) Permeability co-eﬃcient Enhancement ratio
DF6 13.866 0.0009 –
DF7 30.466 0.002 2.197
DF8 39.2 0.0026 2.827
DF9 89.7 0.0059 6.469
DF10 54.3 0.0036 3.916
Table 5 The correlation coefﬁcient and diffusion release exponent value of different ﬁlms.
Film code Correlation coeﬃcient (R2) (mean ± SD, n= 3) Diﬀusion release exponent
(n) (mean ± SD, n= 3)
Zero order kinetics First order kinetics Higuchi kinetics Korsmeyer–Peppas kinetics
DF1 0.897 ± 0.005 0.640 ± 0.023 0.984 ± 0.009 0.974 ± 0.006 0.529 ± 0.005
DF2 0.923 ± 0.018 0.621 ± 0.034 0.991 ± 0.014 0.987 ± 0.018 0.551 ± 0.007
DF3 0.960 ± 0.008 0.811 ± 0.007 0.976 ± 0.031 0.979 ± 0.008 0.682 ± 0.015
DF4 0.959 ± 0.021 0.793 ± 0.003 0.990 ± 0.018 0.991 ± 0.016 0.571 ± 0.009
DF5 0.953 ± 0.005 0.716 ± 0.020 0.989 ± 0.014 0.995 ± 0.008 0.507 ± 0.024
DF6 0.966 ± 0.013 0.787 ± 0.034 0.993 ± 0.007 0.997 ± 0.045 0.550 ± 0.007
DF7 0.968 ± 0.008 0.788 ± 0.021 0.993 ± 0.008 0.998 ± 0.031 0.548 ± 0.003
DF8 0.961 ± 0.004 0.783 ± 0.007 0.992 ± 0.013 0.996 ± 0.005 0.525 ± 0.004
DF9 0.970 ± 0.011 0.791 ± 0.013 0.990 ± 0.015 0.996 ± 0.034 0.531 ± 0.021
DF10 0.963 ± 0.02 0.772 ± 0.002 0.994 ± 0.003 0.996 ± 0.009 0.539 ± 0.002
Transdermal matrix ﬁlm of diltiazem HCl 547The principal monoterpene present in eucalyptus oil is 1,8-
cineole. It was reported that hydrophilic terpenes (alcohol,
ketone and oxide terpenes) were better penetration enhancers
for hydrophilic drugs compared to hydrocarbon containing
terpenes. Again, among oxide terpenes cyclic ethers such as
1,8-cineole are more potent than terpenes containing epoxide
ring [24]. 1,8-cineole is cyclic ether and the mechanism of
action is the disruption of regular arrangements of intercellular
bilayer lipid present in SC [25]. Furthermore, in the molecular
level oxygen-containing monoterpenes such as cineole prefer-
entially make hydrogen bond with ceramide head groups,
thereby, breaking the lateral/transverse hydrogen bond net-
work of lipid bilayer [25]. It was evident (hydrophilic terpenes
are better penetration enhancer for hydrophilic drug) from a
study where there was a 100 times increase in Kp of 5-
ﬂuorouracil (hydrophilic drug) across human epidermis pre-
treated with 1,8-cineole [26]. 1,8-cineole was found to be more
efﬁcient penetration enhancers for another hydrophilic model
drug propranolol hydrochloride at 5% (ﬂux of 49.3
± 5.5 lg/cm2/h) and 10% (93.81 lg/cm2/h) as compared to
menthol and PG [27]. In the present investigation, we wit-
nessed a ﬂux of 89.7 lg/cm2/h at 5% level of cineole suggesting
that these ﬁlms can provide a long-lasting effect. It was
described elsewhere in the literature that PG was used as pen-
etration enhancers for drugs such as 5-ﬂuorouracil, proges-
terone and estradiol [28]. Improvement of ﬂux of bupranolol
by 1.8-fold using PG compared to control was also reported.
Furthermore, PG, present in the ﬁlm as plasticizer, can absorb
moisture from environment because of its humectant activity,
and thereby, enhances the permeation of DTH [28].
Capsaicin is a resin obtained from the plant of capsicum
family. It exerts therapeutic effects on cardiovascular, respira-
tory and sensory nervous system apart from its penetration
enhancement activity. Capsaicin at 3% level has been used
as a penetration enhancer for the topical application ofnaproxen through pretreated full thickness human abdominal
skin and rabbit ear skin and observed that the ER was 2.8-fold
and 3.6-fold for human and rabbit skin, respectively. The
result was attributed to (i) similarity of structure (the longest
axis distance of both compounds is very similar  17 A˚) of
capsaicin to azone (as azone is well established penetration
enhancer), (ii) vasodilatation effect of capsaicin, and (iii) the
predicted logP value for capsaicin is 3.31 that helped capsaicin
molecules to insert itself into the lipid bilayers leading to dis-
ruption of its packed structure [29]. In our study, we found
that the ER of DTH through rat skin was 3.916 which was
more than the previous study. This is attributed to the use of
higher concentration (5% compared to 3% in previous case)
of capsaicin and the rat skin (instead of human skin used in
the previous study) as model membrane. Previous study
reported that the rat skin is considered as more permeable than
human skin [30].
It was reported that pyrrolidones without carbon chain
enter and disrupt the lipophilic domain of SC, whereas,
alkyl-substituted pyrrolidone (NMP) interacts with polar
domain of the SC [31]. So, enhancement effect of NMP was
due to its interaction with lipid present in SC. The solvent
DMSO interacts with the polar head of the lipid and keratin
structure of the corneocytes resulting in loosening of these
structures [32]. Both NMP and DMSO enhance the perme-
ation of polar drugs. We observed that the NMP present in
ﬁlm DF8 showed better enhancement (2.827) than DMSO
(2.197) containing ﬁlm DF7. This result was in accordance
with cyclosporine A retention in the SC of rat using DMSO
and NMP along with other penetration enhancers [33].
In-vivo study
Antihypertensive activity of optimized ﬁlm (DF9) was carried
out by invasive method using rabbit model and the result in
548 R. Parhi and P. Sureshpercentage decrease in blood pressure compared to ve con-
trol group is shown in Fig. 4. The arterial blood pressure
was measured up to 24 h. The result showed a decrease in arte-
rial blood pressure in case of rabbit treated with oral solution
and optimized ﬁlm.
It was reported that invasive method of blood pressure
measurement, where the arterial pressure was measured with
the help of a ﬂuid (mostly heparinized saline) in contact with
blood, gives more accurate result as compared to non-
invasive method [34]. We carried out blood pressure measure-
ment in normotensive rabbits and observed that the antihyper-
tensive activity of rabbit group applied with drug incorporated
ﬁlm was statistically signiﬁcant (P< 0.05) compared to +ve
control group throughout the study. It was also observed that
there was a steep decrease in percentage of arterial blood pres-
sure drop in +ve control group as shown in Fig. 4. Further, at0 
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Fig. 4 Invasive arterial blood pressure comparisons of rabbit
groups treated with oral DTH solution and ﬁlm with DTH with
respect to control group.
Fig. 5 Photomicrographs of section of rat skin: (a)6 h of study the percentage decrease in arterial blood pressure
was 15.79%. This indicated a rapid decrease in drug level in
blood which may be due to short half-life of the drug. Rabbit
group treated with drug loaded ﬁlm showed a constant per-
centage decrease in blood pressure up to 10 h of study and then
it gradually decreases till 24 h. This suggested a sustained anti-
hypertensive activity of DTH when a matrix type of transder-
mal ﬁlm was used as formulation.
Histopathological studies
The penetration enhancing capacity of the optimized ﬁlm
(DF9) containing 1,8-cineole was performed and further com-
pared with untreated skin. The photomicrograph of untreated
skin shows a well deﬁned SC with distinct coenocytes interca-
lated in bilipid layers as shown in Fig. 5(a). Upon treatment
with the DF9, a signiﬁcant increase in SC disruption was
observed (Fig. 5(b)). This was evident from the highly enlarged
intercellular space within SC which conﬁrmed the disruption
lipid bilayer arrangement leading to increase in penetration
of DTH.
Scanning electron microscopic (SEM) and stability studies
The SEMmicrographs of fresh ﬁlm and aged ﬁlm are shown in
Fig. 6(a) and (b). The SEM photographs of fresh ﬁlm showed a
clear and smooth surface indicating uniform distribution of
drug in the polymer matrix (Fig. 6a). A clear and smooth ﬁlm
surface in case of fresh ﬁlm indicates uniform distribution of
drug in the polymer matrix having equal amount of hydrophi-
lic and hydrophobic polymers [9]. This may be due to the good
solubility of drug in hydrophilic polymer (in this case HPMC
K4M). In addition, entrapment of drug molecules in the poly-
meric chain leads to sustained release of the drug from the
ﬁlms [9]. Numbers of white spots were observed in case of aged
ﬁlm (Fig. 6b) suggesting that the crystals of DTH were formeduntreated; (b) treated with optimized ﬁlm (DF9).
Fig. 6 Scanning electron micrographs of the optimized ﬁlm: (a) fresh ﬁlm; (b) 3 months aged ﬁlm.
Transdermal matrix ﬁlm of diltiazem HCl 549during the course of 3 months storage at 40 ± 2 C/75%
± 5%RH. The higher storage temperature may have resulted
in movement/migration of drug particle and deposited on
the nuclei to form the crystals. Similar phenomenon was
also observed when miconazole nitrate was crystallized
out in chitosan-based buccoadhesive ﬁlm at same storage
condition [35].
Conclusions
Diltiazem HCl in ﬁlm DF9 containing equal proportion of
polymers HPMC K4M and Eudragit RS100, and 1,8-cineole
(5%) as penetration enhancer showed highest ﬂux in ex-vivo
study. This result was further supported by the histology study
which demonstrated the mechanism (disorganization of bilipid
layer of SC) of 1,8-cineole. The in-vivo study showed a consis-
tent lowering of arterial blood pressure for the optimized ﬁlm
(DF9) until 10 h. Therefore, it can be concluded that the above
ﬁlm has the potential for transdermal drug delivery of DTH
with improved permeation proﬁle for longer period of time
and thereby increasing the patient compliance.
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